New England Journal of Medicine Releases Study Saying COVID-19 Vaccines Never Prevented Covid-19, “Modest” at Best

New England Journal of Medicine Releases Study Saying COVID-19 Vaccines Never Prevented Covid-19, “Modest” at Best

Join the thousands of free subscribers today! It is totally free! And, you keep NWD going in the face of tyrannical censorship

On June 2, 2022, the NEJM released a study showing the effectiveness of COVID-19 vaccines across the world. The study comes to the conclusion that the vaccines never prevented COVID-19 and most results were “modest” at best.

COVID-19 vaccines and pregnancy: What to know if you're pregnant, trying to  conceive, or breastfeeding - UChicago Medicine

A total of 344 COVID-19 vaccine candidates were developed with only 31 being approved for further testing and large-scale use. Of course, they tested the 31 vaccines on poor people in Africa, India, Mexico and other low-income countries and continents. This is par for the course when we are talking about big pharmaceutical companies. They love to use poor people as lab rats.

At least five different technology platforms have been used (i.e., messenger RNA [mRNA], viral-vectored, inactivated whole-virus, protein subunit, and plasmid DNA approaches).

Many reasons dictate a need for the development of a range of Covid-19 vaccines available for use across the world with the aim of bringing the pandemic under control. Each vaccine product has different attributes and advantages and disadvantages, and multiple factors must be considered to guide policy decisions. Different countries and health care settings, as well as different subpopulations and age groups, may benefit from different vaccine products developed on different platforms. Efficacy and safety, as evaluated in phase 3 trials, are not the sole outcomes to be assessed in a country’s decision to procure and introduce new Covid-19 vaccines. Ease of schedules, vaccine effectiveness when used in routine programs, need and frequency of boosters, cost, considerations regarding cold-chain logistics, manufacturing scalability, acceptability by communities, and scope for local or regional production are additional important factors. - NEJM STUDY

After all the studies were conducted and they had real world results of how well the vaccines would work, the New England Journal of Medicine has concluded that the original batches of vaccines were completely useless and two new vaccines would need to be developed.

To this end, we commend the development of two new vaccines, as now described in two articles in the Journal, one by Hager et al.4 and one by Dai et al.5 Both of these Covid-19 vaccines are produced on new technology platforms: Hager et al. describe a plant-based coronavirus-like particle vaccine, and Dai et al., a receptor-binding domain (RBD)–dimer–based vaccine. - NEJM STUDY

All phases of the study included working-age adults; hence, no vaccine efficacy data are available for older persons who belong the most vulnerable class of people.

Essentially, they are saying they had absolutely no idea if the vaccine would prevent old people from becoming infected with COVID-19 but still forced the vaccines on them anyways.

The study also reveals that no one really had any idea of how well the vaccine would protect pregnant women or people with pre existing health problems, but the vaccines were still pushed upon them as well.

Remember the media saying that pregnant women should be vaccinated? They didn’t have a clue if it was safe for women who were pregnant at all.

Even the CDC published their lies claiming that new data had shown that the vaccines were extremely safe for women who were pregnant.

In conclusion, the study finds that none of the vaccines even prevented COVID-19 and most results were modest at best.

Read the full study here!